ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
 PMID: 28392234       2017       Journal of hepatology
3Introduction: The molecular explanation is that ETV resistance usually requires the LAM-resistant ""YMDD mutation(s)"" (rtM204V/I +-L180M) plus an additional ETV 'signature' substitution in the B domain (rtI169T or rtS184G), C
Result: Other mutations, especially those related to LAM or ETV resistance (rtL180M and rtM204V/I) and classical immune escape (sG145R and/or P120T) variants were noted at no or very low frequencies (Table 1), despite ETV treatment.


  Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
 PMID: 28332360       2017       Yonsei medical journal
Abstract: All subjects with virological rebound (n=5) showed drug-resistant mutation: three had mutation rtM204I, and two had mutation rtM204V.
Result: All five patients with virological rebound had evidence of drug-resistant mutations, with three patients with the rtM204I mutation and two with the rtM204V mutation.


  Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant.
 PMID: 28325923       2017       Emerging microbes & infections
Result: We also screened several mutations relevant to antiviral resistance, such as I169L, L180M, A181V, T184I, S202C, M204V/I, N236T and M250I in the RT region.


  HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
 PMID: 28303969       2017       Scientific reports
Result: After implementing Benjamini-Hochberg correction, 3 (rtM204I, rtL80I, rtY54H) out these 7 RT substitutions and 6 (sS45A, sP46T, sI68T/A, sT118V, sW196L and sR210N) out of 8 S-substitutions remained significantly less frequent in the responders (Table 4).
Result: At 48 week of TDF therapy,


  The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.
 PMID: 28300730       2017       Antiviral therapy
Abstract: RESULTS: A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group.


  Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
 PMID: 28103819       2017       BMC gastroenterology
Abstract: Seven patients (14.9%) exhibited genotypic resistance mutations (M204I +/- L180M) during the virologic breakthrough.
Result: Of these patients, genotypic resistance mutations to Telbivudine (M204I +/- L180M) were detected in seven during the virologic breakthrough.


  Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).
 PMID: 28017671       2017       Journal of global antimicrobial resistance
Abstract: M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.


  Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis.
 PMID: 27871021       2017       Virology
Abstract: Cell lines were transfected with infectious HBV clones encoding surface stop codons rtM204I/sW196*, rtA181T/sW172*, rtV191I/sW182*, and a panel of substitutions in the surface proteins.
Abstract: The most cytopathic variant was rtM204I/sW196*.


  Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
 PMID: 27792585       2017       Microbial drug resistance (Larchmont, N.Y.)
Abstract: For entecavir-resistant mutations, HBV/C-infected patients had a higher detection rate of rtM204 V/I+T184 substitution or S202G/C (3.66% vs. 2.16%, p < 0.01) and a lower detection rate of rtM204 V/I+M250 V/I/L substitution (0.67% vs. 1.46%, p < 0.01).


  Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.
 PMID: 27538443       2017       Gut and liver
Abstract: METHODS: Patients with CLV-resistant CHB were enrolled in the cohort, and all patients developed virologic breakthrough during CLV therapy and had confirmed-genotypic resistance to CLV (rtM204I mutation) before enrollment.
Method: Eligible patients were identified according to the following inclusion criteria: age over 18 years, HBeAg positive or negative CHB, more than 6 months of CLV therapy, development of virologic breakthrough during CLV therapy with confirmed genotypic resistance to CLV (rtM204I mutation), and rescue therapy for CLV-resistance for more than 12 weeks with either ADV, CLV+ADV, LAM+ADV, or ETV.



Browser Board

 Co-occurred Entities




   Filtrator